Viral-vector-based gene therapy (Zolgensma, onasemnogene abeparvovec-xioi) for SMA was approved by the FDA in 2019 to deliver a functional copy of the SMN cDNA as a one-time intravenous administration to patients below the age of 2 years [12]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.